Literature DB >> 15900579

Prevalence of types 16 and 33 is increased in high-risk human papillomavirus positive women with cervical intraepithelial neoplasia grade 2 or worse.

Nicole W J Bulkmans1, Maaike C G Bleeker, Johannes Berkhof, Feja J Voorhorst, Peter J F Snijders, Chris J L M Meijer.   

Abstract

High-risk human papillomavirus (hrHPV) types are causally related to cervical cancer and its high-grade precursor lesions. The risk posed by the different hrHPV types for the development of cervical intraepithelial neoplasia grade 2 or worse (> or =CIN2) needs to be established. Here, we present the hrHPV type-distribution in relation to cytology and histology for women participating in a cervical screening program. From 44,102 women who participated in a population-based cervical screening program in the Netherlands, 2,154 hrHPV GP5+/6+ PCR positive women were recruited to determine the distribution of 14 hrHPV types by reverse line blotting of GP5+/6+ PCR products. For each HPV type, associations with cytology and histologically confirmed > or =CIN2 were measured by odds ratios. HPV types 16 and 33 were more prevalent in women, amongst those containing a single hrHPV type, with moderate dyskaryosis or worse (>BMD) than in women with normal cytology, but only in case of underlying > or =CIN2 (OR 4.10, 95%CI 2.98-5.64 and OR 2.68, 95%CI 1.39-5.15, respectively). Similar results were obtained for women with double infections (OR 3.29, 95% CI 1.61-6.75 and OR 4.37, 95% CI 1.17-16.34). Coexisting types did not influence the prevalence of > or =CIN2 in HPV 16 or 33 positive women. The increased prevalence of type 16 and 33 in hrHPV positive women with > or =CIN2, compared to women with normal cytology, suggests that infection with these types confers an increased risk for development of > or =CIN2. Distinguishing these types may therefore have implications for future cervical screening strategies.

Entities:  

Mesh:

Year:  2005        PMID: 15900579     DOI: 10.1002/ijc.21210

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  20 in total

1.  Pilot study of a commercialized human papillomavirus (HPV) genotyping assay: comparison of HPV risk group to cytology and histology.

Authors:  Philip E Castle; Mark Sadorra; Francisco Garcia; E Blair Holladay; Janet Kornegay
Journal:  J Clin Microbiol       Date:  2006-09-13       Impact factor: 5.948

2.  Bead-based multiplex genotyping of human papillomaviruses.

Authors:  Markus Schmitt; I G Bravo; Peter J F Snijders; Lutz Gissmann; Michael Pawlita; Tim Waterboer
Journal:  J Clin Microbiol       Date:  2006-02       Impact factor: 5.948

3.  Cross-sectional comparison of an automated hybrid capture 2 assay and the consensus GP5+/6+ PCR method in a population-based cervical screening program.

Authors:  A T Hesselink; N W J Bulkmans; J Berkhof; A T Lorincz; C J L M Meijer; P J F Snijders
Journal:  J Clin Microbiol       Date:  2006-10       Impact factor: 5.948

4.  A population-based study of human papillomavirus genotype prevalence in the United States: baseline measures prior to mass human papillomavirus vaccination.

Authors:  Cosette M Wheeler; William C Hunt; Jack Cuzick; Erika Langsfeld; Amanda Pearse; George D Montoya; Michael Robertson; Catherine A Shearman; Philip E Castle
Journal:  Int J Cancer       Date:  2012-06-20       Impact factor: 7.396

5.  Comparison of the clinical performance of PapilloCheck human papillomavirus detection with that of the GP5+/6+-PCR-enzyme immunoassay in population-based cervical screening.

Authors:  A T Hesselink; D A M Heideman; J Berkhof; F Topal; R P Pol; C J L M Meijer; P J F Snijders
Journal:  J Clin Microbiol       Date:  2009-12-30       Impact factor: 5.948

6.  High concordance of results of testing for human papillomavirus in cervicovaginal samples collected by two methods, with comparison of a novel self-sampling device to a conventional endocervical brush.

Authors:  Antoinette A T P Brink; Chris J L M Meijer; Maarten A H M Wiegerinck; Thedoor E Nieboer; Roy F P M Kruitwagen; Folkert van Kemenade; Nathalie Fransen Daalmeijer; Albertus T Hesselink; Johannes Berkhof; Peter J F Snijders
Journal:  J Clin Microbiol       Date:  2006-07       Impact factor: 5.948

7.  HPV vaccination and cervical cancer.

Authors:  Anne Szarewski
Journal:  Curr Oncol Rep       Date:  2012-12       Impact factor: 5.075

8.  A comparison of linear array and hybrid capture 2 for detection of carcinogenic human papillomavirus and cervical precancer in ASCUS-LSIL triage study.

Authors:  Patti E Gravitt; Mark Schiffman; Diane Solomon; Cosette M Wheeler; Philip E Castle
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-05       Impact factor: 4.254

9.  Human papillomavirus genotyping using an automated film-based chip array.

Authors:  Maria Erali; David C Pattison; Carl T Wittwer; Cathy A Petti
Journal:  J Mol Diagn       Date:  2009-07-30       Impact factor: 5.568

10.  Development and validation of a HPV-32 specific PCR assay.

Authors:  Nicholas R Herrel; Nadia L Johnson; Jennifer E Cameron; Janet Leigh; Michael E Hagensee
Journal:  Virol J       Date:  2009-06-27       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.